We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AMRI Announces Research Collaboration with Achaogen
News

AMRI Announces Research Collaboration with Achaogen

AMRI Announces Research Collaboration with Achaogen
News

AMRI Announces Research Collaboration with Achaogen

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AMRI Announces Research Collaboration with Achaogen"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Albany Molecular Research, Inc. has entered into natural products-based drug discovery collaboration with Achaogen, Inc.

Under the terms of the agreement, AMRI will use its high throughput screening capability to test samples from its natural product libraries for activity against targets of interest to Achaogen.

AMRI will provide a full-range of natural product-based discovery services, including fermentation, fractionation and structure elucidation. In addition, at Achaogen’s option, AMRI may also provide follow-up services such as fermentation optimization and scale-up, biocatalysis and semi-synthetic chemistry.

The collaboration will support Achaogen’s work with the Defense Threat Reduction Agency (DTRA), an agency of the U.S. Department of Defense. The agreement includes an upfront payment and opportunities for AMRI to receive milestone payments based on the achievement of specific development goals.

Moreover, AMRI would receive royalty payments on net sales of any commercial products that result from the collaboration. More specific financial terms were not disclosed.

“We are pleased to be working with Achaogen on this critically important research project,” said Bruce J. Sargent, Ph.D., vice president for discovery R&D at AMRI. “Achaogen’s research targets could hold the promise for development of new treatments for antibiotic resistance.”

With almost 300,000 crude and partially purified fractions, AMRI has diverse natural products-based collections derived from microbial cultures, plants and marine organisms.

Advertisement